Mavekræft kliniske forsøg i Illinois
19 studier for Mavekræft søger deltagere på steder i Illinois.
Byer i Illinois
- Chicago16 studier
- Evanston4 studier
- Springfield3 studier
- Peoria3 studier
- Bloomington3 studier
- Galesburg3 studier
- North Peoria3 studier
- Waukegan3 studier
Officiel studietekst (engelsk)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- OSF Saint Anthony's Health Center, Alton
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- og 31 flere
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- og 54 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06172478A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0379, Chicago
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07221149Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Illinois Cancer Specialists, Arlington Heights
- Illinois CancerCare - Bloomington, Bloomington
- Illinois Cancer Specialists, Chicago
- og 7 flere
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07392892Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Chicago, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Chicago
- Research Site, Niles
- Research Site, Zion
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07431281Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- University of Chicago, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT04107077Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Orchard Healthcare Research Inc., Skokie
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT06731478A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Ingalls Family Care Center, Calumet City
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- og 13 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT04389632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. jun. 2026 · NCT05005403A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- University of Chicago Medical Center, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 27. mar. 2026 · NCT06395519A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Northwestern University, Chicago
- University of Chicago, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 27. feb. 2026 · NCT06532006A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
- University of Chicago, Chicago
RekruttererFase 1/2
Alder 18 til 85 · Alle køn · Opdateret 29. jan. 2026 · NCT06055439SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
- The University of Chicago, Chicago
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 1. okt. 2025 · NCT01416714A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT05107674Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.